Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing, R&D, and Technology Over Next Four Years

On March 21, Johnson & Johnson (NYSE:JNJ), the leading and most comprehensive innovator in the healthcare industry based in New Jersey, announced that it will invest more than $55 billion in manufacturing, research and development, and technology in the United States over the next four years. This represents a 25% increase in investment compared to the previous four years and builds on the company's already elevated U.S. investment levels following the passage of the 2017 Tax Cuts and Jobs Act.

Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, said:"Today's announcement accelerates our legacy of nearly 140 years as an engine of innovation in the United States, tackling some of the world's toughest healthcare challenges. Our increased U.S. investment begins with the groundbreaking of a high-tech facility in North Carolina that will not only add jobs in the U.S. but also produce cutting-edge medicines to treat patients across the U.S. and around the world."

$55 Billion Investment to Support U.S. Innovation and Manufacturing

In addition to the plant in Wilson, North Carolina, the company's increased investments in the U.S. over the next four years will include:

Three new advanced manufacturing plants and the expansion of several existing plants in the company's innovative medicine and medical technology businesses will create high-paying, high-tech jobs. The company will share more information on these sites.

Significant investment in extensive R&D infrastructure aims to develop life-saving and life-changing treatments in the fields of oncology, neuroscience, immunology, cardiovascular diseases, and robotic surgery.

Increase technology investment to help accelerate drug discovery and development, support workforce training, and strengthen our business operations.

With increased investment over the next four years, the company's economic impact on the U.S. will build on its already estimated annual figure of more than $100 billion.

North Carolina Breaks Ground Today, Launching U.S. Investment

Starting today, investments in North Carolina will create jobs in Wilson, North Carolina, where the company will officially break ground on its 500,000-square-foot, state-of-the-art biologics manufacturing facility.

The plant in North Carolina will:

Expand our capacity to produce next-generation medicines for patients with cancer, immune-mediated diseases, and neurological disorders in the United States and around the world.

Support approximately 5,000 jobs during construction and create more than 500 positions in North Carolina.

In the first 10 years of operation, it generated a $3 billion impact across the state.

Johnson & Johnson has more manufacturing plants in the United States than in any other country and is a leading investor in American innovation and research and development. The company focuses on pharmaceuticals and medical technology, making a unique impact on various diseases. From cardiology to cancer, from mental health to vision, from cell therapy to robotics, the depth and breadth of Johnson & Johnson's expertise and capabilities are unparalleled. No other company can compare with Johnson & Johnson in providing first-class solutions at every step of the patient journey.

Follow the official account below to see the world!